Beyond histology: translating tumor genotypes into clinically effective targeted therapies.
Beyond histology: translating tumor genotypes into clinically effective targeted therapies.
复制标题
DOI：
10.1158/1078-0432.ccr-13-1591
复制
发表时间：
2014-05-01
期刊：
影响因子：
--
通讯作者：
Pao W
中科院分区：
文献类型：
--
作者：
Meador CB;Micheel CM;Levy MA;Lovly CM;Horn L;Warner JL;Johnson DB;Zhao Z;Anderson IA;Sosman JA;Vnencak-Jones CL;Dahlman KB;Pao W
在基因组水平上对肿瘤间异质性的理解的增加导致了实体瘤治疗的显著进步。赋予靶向治疗敏感性的功能性基因组改变可以采取多种形式，并且需要适当的方法和工具来检测这些改变。本文以非小细胞肺癌（NSCLC）和黑色素瘤为例，对相似组织学分类的实体瘤之间的遗传变异性进行了综述。我们还讨论了用于发现和诊断临床上可操作的变体的相关技术平台，并强调了特定基因组改变对靶向治疗反应的影响。
Increased understanding of inter-tumoral heterogeneity at the genomic level has led to significant advancements in the treatment of solid tumors. Functional genomic alterations conferring sensitivity to targeted therapies can take many forms, and appropriate methods and tools are needed to detect these alterations. This review provides an update on genetic variability among solid tumors of similar histologic classification, using non-small cell lung cancer (NSCLC) and melanoma as examples. We also discuss relevant technological platforms for discovery and diagnosis of clinically actionable variants and highlight the implications of specific genomic alterations for response to targeted therapy.